Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tovinontrine
- Development stage
- Discontinued
- Lead developer
- Cardurion Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Tovinontrine is an orally administered, highly selective small molecule inhibitor of phosphodiesterase 9 (PDE9). It was originally developed for the treatment of sickle cell disease and beta-thalassemia but development for these indications has been discontinued due to lack of efficacy. Currently, it is being investigated in Phase II clinical trials for chronic heart failure, including both heart failure with preserved ejection fraction (HFpEF) and reduced ejection fraction (HFrEF). The drug works by inhibiting PDE9A, which increases levels of cyclic guanosine monophosphate (cGMP), a signaling molecule involved in vascular relaxation and cardiac function. By modulating cGMP pathways, tovinontrine may improve cardiac performance and reduce symptoms associated with heart failure[1][2][3][4][6][7].
- Other names
- Tovinontrine [USAN]TOVINONTRINE [INN]TOVINONTRINE [WHO-DD]
02
Targets
PDE9A (Phosphodiesterase 9A)
Beyond the preview
Go deeper on tovinontrine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tovinontrine.